CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 25 of 124 entries

View as:

Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

Phase: N/A Priority: Normal

NCT ID: NCT05838053 Org: User:

Start: 08/20/19 End: 04/30/28 Due: 04/30/29

Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study

Phase: N/A Priority: Normal

NCT ID: NCT06216782 Org: User:

Start: 12/16/23 End: 12/30/33 Due: 12/30/34

NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Phase: N/A Priority: Normal

NCT ID: NCT03764917 Org: User:

Start: 12/01/18 End: 12/31/21 Due: 12/31/22

Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT06895941 Org: User:

Start: 04/30/25 End: 04/01/27 Due: 04/01/28

Neoadjuvant Treatment For Locally Advanced Thymic Cancer

Phase: N/A Priority: Normal

NCT ID: NCT06019468 Org: User:

Start: 09/04/23 End: 12/30/25 Due: 12/30/26

Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma

Phase: N/A Priority: Normal

NCT ID: NCT04716751 Org: User:

Start: 02/01/21 End: 05/31/25 Due: 05/31/26

Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT04422392 Org: User:

Start: 07/13/20 End: 09/30/22 Due: 09/30/23

Post-line Treatment with Teniposide for C-Myc-driven Extensive-stage Small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT06758700 Org: User:

Start: 01/07/25 End: 12/31/25 Due: 12/31/26

NTM-LD Treatment Based on GenSeizer Characteristic Gene Capture Strategy

Phase: N/A Priority: Normal

NCT ID: NCT03224065 Org: User:

Start: 10/09/17 End: 09/30/20 Due: 09/30/21

Robot-assisted vs VATS for Thymoma

Phase: N/A Priority: Normal

NCT ID: NCT06029621 Org: User:

Start: 11/20/23 End: 09/19/30 Due: 09/19/31

Rapid and Accurate Detection of Major Mycobacterium Species in Pulmonary Infection Based on GenSeizer Platform

Phase: N/A Priority: Normal

NCT ID: NCT04345939 Org: User:

Start: 06/28/21 End: 08/30/24 Due: 08/30/25

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Phase: N/A Priority: Normal

NCT ID: NCT02546297 Org: User:

Start: 09/15/17 End: 03/01/21 Due: 03/01/22

Clinical Characteristics of Lung Cancer in China

Phase: N/A Priority: Normal

NCT ID: NCT05423236 Org: User:

Start: 07/01/22 End: 06/30/23 Due: 06/30/24

Application of SERS Technology in Clinical Diagnosis and Prognosis of Lung Cancer Immunotherapy

Phase: N/A Priority: Normal

NCT ID: NCT05885815 Org: User:

Start: 06/30/23 End: 06/30/25 Due: 06/30/26

Idiopathic Bronchiectasis and Pulmonary Hypertension

Phase: N/A Priority: Normal

NCT ID: NCT03883048 Org: User:

Start: 06/01/18 End: 12/31/21 Due: 12/31/22

Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients

Phase: N/A Priority: Normal

NCT ID: NCT04696939 Org: User:

Start: 01/31/21 End: 10/31/23 Due: 10/31/24

Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT05425134 Org: User:

Start: 01/01/22 End: 12/31/23 Due: 12/31/24

Identification of Microbiome and Metabolome of Bronchiectasis in Chinese Population.

Phase: N/A Priority: Normal

NCT ID: NCT04490447 Org: User:

Start: 08/01/19 End: 09/01/21 Due: 09/01/22

Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT05965024 Org: User:

Start: 10/25/23 End: 08/31/28 Due: 08/31/29

Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC

Phase: N/A Priority: Normal

NCT ID: NCT04372732 Org: User:

Start: 09/30/20 End: 08/31/22 Due: 08/31/23

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT04685070 Org: User:

Start: 12/14/21 End: 12/31/27 Due: 12/31/28

Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules

Phase: N/A Priority: Normal

NCT ID: NCT04554875 Org: User:

Start: 01/01/19 End: 07/01/21 Due: 07/01/22

Screening for Cystic Fibrosis and Cystic Fibrosis Related Disorders in Chinese Adults With Bronchiectasis

Phase: N/A Priority: Normal

NCT ID: NCT05604495 Org: User:

Start: 09/07/22 End: 12/31/24 Due: 12/31/25

LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT06479759 Org: User:

Start: 01/12/24 End: 12/12/25 Due: 12/12/26

The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients

Phase: N/A Priority: Normal

NCT ID: NCT06496009 Org: User:

Start: 07/08/24 End: 04/28/27 Due: 04/28/28

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm	NCT05838053	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2019-08-20	2028-04-30	2029-04-30	-	-	2025-07-14
Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study	NCT06216782	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-12-16	2033-12-30	2034-12-30	-	-	2025-07-14
NGS Combined With RNAseq on Tumor Immune Escape in NSCLC	NCT03764917	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2018-12-01	2021-12-31	2022-12-31	-	-	2025-07-14
Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer	NCT06895941	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2025-04-30	2027-04-01	2028-04-01	-	-	2025-07-14
Neoadjuvant Treatment For Locally Advanced Thymic Cancer	NCT06019468	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-09-04	2025-12-30	2026-12-30	-	-	2025-07-14
Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma	NCT04716751	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-02-01	2025-05-31	2026-05-31	-	-	2025-07-14
Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer	NCT04422392	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2020-07-13	2022-09-30	2023-09-30	-	-	2025-07-14
Post-line Treatment with Teniposide for C-Myc-driven Extensive-stage Small Cell Lung Cancer	NCT06758700	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2025-01-07	2025-12-31	2026-12-31	-	-	2025-07-14
NTM-LD Treatment Based on GenSeizer Characteristic Gene Capture Strategy	NCT03224065	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2017-10-09	2020-09-30	2021-09-30	-	-	2025-07-14
Robot-assisted vs VATS for Thymoma	NCT06029621	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-11-20	2030-09-19	2031-09-19	-	-	2025-07-14
Rapid and Accurate Detection of Major Mycobacterium Species in Pulmonary Infection Based on GenSeizer Platform	NCT04345939	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-06-28	2024-08-30	2025-08-30	-	-	2025-07-14
Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis	NCT02546297	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2017-09-15	2021-03-01	2022-03-01	-	-	2025-07-14
Clinical Characteristics of Lung Cancer in China	NCT05423236	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2022-07-01	2023-06-30	2024-06-30	-	-	2025-07-14
Application of SERS Technology in Clinical Diagnosis and Prognosis of Lung Cancer Immunotherapy	NCT05885815	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-06-30	2025-06-30	2026-06-30	-	-	2025-07-14
Idiopathic Bronchiectasis and Pulmonary Hypertension	NCT03883048	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2018-06-01	2021-12-31	2022-12-31	-	-	2025-07-14
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients	NCT04696939	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-01-31	2023-10-31	2024-10-31	-	-	2025-07-14
Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer	NCT05425134	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2022-01-01	2023-12-31	2024-12-31	-	-	2025-07-14
Identification of Microbiome and Metabolome of Bronchiectasis in Chinese Population.	NCT04490447	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2019-08-01	2021-09-01	2022-09-01	-	-	2025-07-14
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer	NCT05965024	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-10-25	2028-08-31	2029-08-31	-	-	2025-07-14
Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC	NCT04372732	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2020-09-30	2022-08-31	2023-08-31	-	-	2025-07-14
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer	NCT04685070	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-12-14	2027-12-31	2028-12-31	-	-	2025-07-14
Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules	NCT04554875	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2019-01-01	2021-07-01	2022-07-01	-	-	2025-07-14
Screening for Cystic Fibrosis and Cystic Fibrosis Related Disorders in Chinese Adults With Bronchiectasis	NCT05604495	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2022-09-07	2024-12-31	2025-12-31	-	-	2025-07-14
LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer	NCT06479759	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2024-01-12	2025-12-12	2026-12-12	-	-	2025-07-14
The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients	NCT06496009	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2024-07-08	2027-04-28	2028-04-28	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance